Avalon globocare advances ai-enhanced protein design technology for cellular therapy development

Freehold, n.j., dec. 09, 2021 (globe newswire) -- avalon globocare corp. (nasdaq: avco) (avalon or the company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced further advancement of the company's sponsored research and licensing agreement with the massachusetts institute of technology (mit). avalon and mit have combined their artificial intelligence (ai)-enhanced protein design “qty code” technology with google's alphafold2, a deepmind ai program developed to predict 3-dimensional (3d) protein structures of previously difficult to work with drug targets. this new system is designed to accelerate and advance avalon's capabilities in developing novel targets for immuno-oncology and cellular medicine.
AVCO Ratings Summary
AVCO Quant Ranking